Latest news with #MSD
Business Wire
a day ago
- Business
- Business Wire
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free) or (517) 308-9448 and using the access code 9818590. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Scoop
2 days ago
- Business
- Scoop
Increased Accountability For Jobseeker Support
Minister for Social Development and Employment From today, people getting Jobseeker Support will need to reapply every 26 weeks (six months), instead of just once a year, Social Development and Employment Minister Louise Upston says. 'This previously signalled change increases accountability, while also improving opportunities for jobseekers,' Louise Upston says. 'Reapplying for their benefit more often makes sure people receiving Jobseeker Support engage with MSD more regularly. Frontline staff are then able to check people are doing everything they can to find a job and prepare for work, while getting the right kind of support from MSD to make that happen. 'It also gives MSD another opportunity to assess people's eligibility and make sure they understand what they need to do to stay on track with their obligations while receiving a benefit. 'We know getting back into work produces better outcomes for people and their families. Reapplying for Jobseeker Support every 26 weeks instead of 52 is a realistic expectation, as part of the Government's initiatives to actively support people off welfare and into employment. 'Having to apply only once a year was a significant gap and didn't help either jobseekers or the MSD staff working with them.' Changes have also been made to the reapplication process to make it easier for many people reapplying. If they've recently interacted with MSD about their job search, for instance, they may be able to complete their reapplication online without needing an appointment. 'The improved reapplication process means less time repeating information and more time focusing on support to overcome barriers to work,' Louise Upston says. Notes: For people already getting Jobseeker Support on 1 July 2025, the date they will need to reapply depends on when their benefit was last granted and their situation. Some clients will reapply at 52 weeks from when their benefit was last granted where they are current subject to annual income charging, and then every 26 weeks after that. 26-week reapplications were introduced as a part of the suite of changes made by the Social Security Amendment Act 2025.
Irish Examiner
5 days ago
- Business
- Irish Examiner
MSD developing talent for business-critical positions
Biopharmaceutical company MSD's Manufacturing Leadership Development Program is designed to develop emerging talent for business-critical positions of increasing responsibility within its Manufacturing Division, the part of the company devoted to formulating, packaging and distributing its products. Participants are placed in rotations that represent key business priorities to foster their development, and a learning and development plan helps to supplement the rotational experience. A mentoring program is provided at three levels to coach each participant in career and leadership development. Annual program meetings facilitate a tight-knit network, with all program members receiving a competitive salary and access to the full benefits programs offered by the company. Successful candidates are new college graduates with a bachelor's or master's degree in key STEM or supply chain majors, and participants are selected through a rigorous assessment process to evaluate academic understanding in their fields as well as demonstrated leadership potential. 'The Manufacturing Leadership Development Program is an important part of our Manufacturing Division,' says Ashley Suarez, Associate Director, Manufacturing Leadership Development Program. Members are impactful contributors to the critical business needs of MMD and are active in taking stretch assignments to grow their career. They are an energized group of the future leaders at our company.' Moushmi Culver, Vice President Manufacturing Strategy, Business Development and Alliances, adds: 'The Manufacturing Leadership Development Program participants bring strong technical and leadership skills coupled with innovative thinking to invigorate and help shape the future of our company's Manufacturing Division. As an alumna of the program, it is incredible to sponsor talent recruitment and development of this team.' Jen Hanrahan, Director, Manufacturing Leadership Development Program says: 'The Manufacturing Leadership Development Program allows for the MLDPs to get real-world manufacturing experience. It is incredible to watch the LDPs thrive in a highly complex, global work environment while continuing to enhance their technical and leadership skills.'
Yahoo
25-06-2025
- Health
- Yahoo
NSC Invests $300,000 in Next-Generation Solutions for Safer Workplaces
Grants advance research and pilot programs to prevent musculoskeletal disorders WASHINGTON, June 25, 2025 /PRNewswire/ -- The National Safety Council awarded $300,000 to the 2025-2026 Research to Solutions (R2S) and MSD Solutions Pilot Grant recipients, bringing the total investment in musculoskeletal disorders (MSDs) prevention to nearly $850,000 over three years. The grants support academic research and workplace pilot programs through the NSC MSD Solutions Lab, established in 2021 with funding from Amazon (NASDAQ: AMZN). The programs focus on preventing musculoskeletal disorders, the most common workplace injury in America. This year's awardees were announced during the Workplace Safety Summit: Innovation to Application, held during National Safety Month. The event spotlighted pioneering research and innovative strategies to mitigate MSDs. The lab also celebrated the third anniversary of its signature MSD Pledge initiative, which now includes nearly 250 organizations representing 3 million employees worldwide. "Each year, the MSD Solutions Lab grants spark innovative thinking and fresh solutions to one of the most pressing workplace challenges," said Katherine Mendoza, senior director of workplace safety programs at NSC. "This year's recipients exemplify the kind of bold, actionable ideas needed to create safer working environments." The R2S grant supports academic institutions researching MSD interventions. Each selected project receives up to $50,000 to explore areas such as emerging technologies, risk-prone job tasks, MSD management systems and total worker wellbeing. This year's recipients include: University of Waterloo, a second-time grant recipient, will use innovative MSD risk assessment tools to better leverage data from emerging technologies Auburn University will test a new plant-layout organizational tool for MSD control and mitigation Texas Tech University will assess 3D printed head and neck rests for reduced discomfort during overhead work George Mason University will develop smartphone computer vision technology for real-time movement assessment to prevent MSDs in emergency responders The MSD Solutions Pilot Grant supports the trial of safety innovations through partnerships between MSD Pledge members and leading technology providers. Each recipient receives $20,000 to implement and evaluate promising solutions aimed at reducing MSD risks. This year's recipients include: dormakaba will partner with DORN to train employees in MSD risk reduction best practices to improve overall wellness Cargill will work with MākuSafe to explore how technology can be used to create risk profiles and provide early hazard identification Panduit will team with Stroma Vision to help reduce upper extremity MSD risks in cable management and electrical connectivity manufacturing operations Northwell will collaborate with Hapo to validate the benefits of a "surgeon exoskeleton" in reducing upper limb strain during long, complex surgical procedures US Foods will use IntelliSafe Analytics to identify lifting stress incidents at manufacturing facilities and delivery sites This year's grant recipients will have the opportunity to present their findings at the 2026 NSC Safety Congress & Expo. For more information about the MSD Solutions Lab and grant programs, visit About the National Safety CouncilThe National Safety Council is America's leading nonprofit safety advocate – and has been for over 110 years. As a mission-based organization, we work to eliminate the leading causes of preventable death and injury, focusing our efforts on the workplace and roadways. We create a culture of safety to not only keep people safer at work, but also beyond the workplace so they can live their fullest lives. Connect with NSC:FacebookTwitterLinkedInYouTubeInstagram View original content to download multimedia: SOURCE National Safety Council Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Irish Examiner
25-06-2025
- Health
- Irish Examiner
IFA urge the department to do more to secure Lepto vaccines
The announcement that production of the Leptavoid-H vaccine will cease has caused major concern, with many Irish farmers now left scrambling in search of an alternative. It comes after MSD recently announced it will cease production of its widely used Leptavoid-H vaccine, which is used by stock keepers to prevent Leptospirosis, a bacterial disease in cattle. Leptospirosis can cause abortions, decrease fertility and reduce milk production in cattle. This bacterial disease is also zoonotic, meaning that humans can potentially contract the disease from infected animals. 'This will create a serious issue for farmers who are due to administer a lepto vaccine to their herd in the coming months... This could mean that a lot of cattle herds will lose protection from Leptospirosis if they miss their annual booster shot,' said IFA Animal Health Chair TJ Maher. The IFA Animal Health Chair outlined that the availability of vaccines when needed is "critical" for farmers in protecting and maintaining the health, welfare and productivity of our animals while reducing antibiotic usage. 'Farmers have experienced increasing shortages of certain vaccines at critical times, and here we are with the same problem yet again... These vaccines are too important to animal and human health; we cannot have situations where these vaccines become unavailable to farmers,' he added. Commenting on MSD's decision to end production of the vaccine, Jack O'Connor, MSD Ruminant Unit Business Director, said: 'Bovilis Leptavoid-H was developed more than 30 years ago, and while this unique vaccine has a strong safety and efficacy profile, it has always proven very difficult to produce, creating recurrent supply challenges. "Despite multiple years of improvement and remediation efforts, we have not been able to consistently supply the market with a product that meets our strict quality standards. Therefore, we have had to make the difficult decision to discontinue the product.'
